Joshua Waldman: Got it. Okay. And then Prahlad, can you talk about any momentum you’re seeing in key accounts as it relates to Revvity’s ability to cross-sell or realize commercial synergies following the divesture and rebranding? I guess are there any specific examples you can point to of how Revvity is making progress towards being a more effective strategic partner specifically within pharma?
Prahlad Singh: Yes, Josh, I think and I mentioned that during one of the healthcare conferences earlier in January our example with one of our most important customers that we talked about in the pharma side is how we are able to leverage our relationship both in the Diagnostic and the Life Sciences side of the portfolio to not only license technology to them, but also provide the tools and capabilities and our service offering from the DX side that allows for being part of the journey of drug development for our important customers all the way from preclinical research and licensing them the technology, providing them the tools and capabilities that allows them to use and leverage that technology towards drug development and then being part of the journey with them through their development process as they take it through the regulatory approval processes and then further on leveraging our global lab infrastructure from the Omic side of the business to be able to follow up those patients both for efficacy of the drug and for follow ups.
So that sort of allows us initially when we were on the small molecule side in Life Sciences, our focus was on providing them the reagents and tools and instruments and pre in vivo imaging components to just do their research. Now, with the full expansion of our portfolio, it allows us to be with them from the start to when it gets to commercialization.
Operator: The next question today comes from the line of Patrick Donnelly from Citi.
Patrick Donnelly: Hey, good morning, guys. Thanks for taking the questions. Probably one for Max on the margin side. Understand this year more flattish given the revenue outlook. It sounds like you guys are continuing to implement some cross plan there. Can you just talk about the confidence in that 75 bps expansion algorithm that you guys talked about at JPM and just this becoming that 30-plus percent margin business in the relative near term? What are the key levers you see? And maybe just the process that went into revisiting that algorithm. Did you guys want to set it more as a floor where you saw a clear path to executing on it? Even the China piece sounds like you’re chasing more profitability there. So maybe just kind of pull the current back a little on the margins and again that algorithm you guys set.
Max Krakowiak : Yes, sure. Hey, Patrick. So as we step back and look at it from a margin perspective, I think that 75 basis points, it was taken down from the previous MRP of 75 to 100 basis points. And that was mostly just attributed, I think, to the change in the top line assumptions. If you look at the assumption of the market on average is growing four to six were a couple hundred basis points better than that. That’s going to drive natural operating leverage just from a pure growth perspective and so even in addition to that I think where we have confidence in sort of the margin expansion is really still the fact that we’re still in the early innings of what the actual overall structure of this company should be given all the transformation, right?
In terms of the number of acquisitions and integrating them into our core business and processes as well as sort of working our way through all the standard costs related to the divestiture. So I think we have a lot of spokes irons in the fire from an op margin expansion standpoint outside of just the natural volume leverage you would get. I think there is a high degree of confidence and in terms of your question in terms of the amount of conservative or whether it’s a floor. I think we thought it was a fair number that we can consistently deliver on with that expected growth algorithm.
Patrick Donnelly: Okay, that’s helpful and Prahlad, maybe just on China, something you guys talked a little about the ImmunoDX on an earlier question but just in terms of this year what you’re seeing their confidence both on the Diagnostic and then the Life Sciences side which is obviously a little more variable, again it sounds like you guys are making some changes in terms of going after a little more profitable business which is the outlook in China confidence in that region and what you’re seeing here near term? Thank you.
Prahlad Singh: Yes, Patrick, I think nothing’s changed in our view regarding China and that level of confidence is because of the portfolio differentiation. I mean this is where I think it really comes down to a good understanding of the markets and the segments where we play in that market And if you just look at the portfolio that we have built out over there. In terms of Life Sciences side, I think on the instrumentation side, we will continue to see some pressure which is not very different from the other global markets. But I think on the reagents side, we will continue to see it coming back. On the immunodiagnostic side, I think excluding the impact of what Max talked about for a small legacy business that helps us improve profitability, it is going to be on a continued growth trajectory.
Newborn screening is going to get impacted, but we’ve got quite a few of our reagents that are awaiting an MPA approval, and hopefully they will compensate for the pressure that we will see from the birth rate decline. So overall, I think it again comes back to the differentiation of our portfolio in China and outside of China. The lower, it sort of risk mitigates our portfolio, both the exposure to the Diagnostics, Life Sciences and the Software market, which sort of in the longer run is going to be the competitive advantage that we will have.
Operator: The next question today comes from the line of Andrew Cooper from Raymond James.
Andrew Cooper: Hey, everyone. Thanks for the questions. Maybe first want to talk about margins a little bit more just for this year. You have modest top line organic growth. You’ve got a 100 bps coming from price and cost action. So I guess what are some of the counter points to prevent being maybe a little bit of expansion year-over-year in ‘23 or maybe asking me the different way, what’s the threshold of revenue growth you need to see to actually see that margin expansion?
